TKIs targeting ERBB2 have limited activity in patients with ERBB2-positive tumors [37,38], although some case series have reported that lung cancer patients with ERBB2 20ins can benefit from TKIs, such as afatinib [39] and poziotinib [40]. The gene discussed is ERBB2; the disease is lung cancer.